Business Context and Reporting Period
Company: Dogwood Therapeutics, Inc. (DWTX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2025
Reporting Period: Single event date (September 29, 2025)
Business Context: The Company is an emerging growth company focused on therapeutic development. This filing reports the entry into a material definitive licensing agreement and related equity issuances.
Key Financial Metrics and Transaction Details
Note: This Form 8-K reports a specific corporate transaction and does not contain standard periodic financial statements (revenue, profit, cash flow, or debt levels).
- Transaction Type: Exclusive Licensing Agreement for the development of SP16 (a first-in-class LRP1 agonist for chemotherapy-induced peripheral neuropathy).
- Counterparties: Serpin Pharma Inc. and Rejuvenation Labs, Inc. (collectively "Serpin").
- Consideration Issued to Serpin Parties:
- Serpin Pharma: 191,017 shares of Common Stock and 89.5939 shares of Series A-2 Non-Voting Convertible Preferred Stock.
- Rejuvenation Labs: 191,017 shares of Common Stock and 89.5939 shares of Series A-2 Non-Voting Convertible Preferred Stock.
- Consideration Issued to Advisor: 10.8694 shares of Series A-2 Preferred Stock issued to Tungsten Advisors (and affiliates) for financial advisory services.
- Licensing Terms: Royalty-free, sublicensable global license.
Material Changes and Corporate Actions
- Equity Issuance: Unregistered sales of equity securities (Common Stock and Series A-2 Preferred Stock) were made in reliance on Section 4(a)(2) of the Securities Act of 1933.
- Preferred Stock Designation: The Company filed a Certificate of Designation for the Series A-2 Non-Voting Convertible Preferred Stock.
- Conversion: Each share converts into 10,000 shares of Common Stock following stockholder approval, subject to beneficial ownership limitations.
- Voting Rights: Generally non-voting, but holders have veto rights over adverse changes to their rights, issuance of additional Series A-2 stock, and fundamental transactions (mergers/sales) while at least 30% of the original issuance remains outstanding.
- Liquidation: Ranks on parity with Common Stock.
- Support Agreements: Entered into stockholder support agreements with Serpin, Tungsten, and Sealbond Limited to vote in favor of specific proposals (including the issuance of Common Stock upon conversion of Series A, A-1, and A-2 Preferred Stock) at an upcoming stockholder meeting.
Guidance, Outlook, and Risks
- Outlook: Management views SP16 as having potential to treat chemotherapy-induced peripheral neuropathy due to its anti-inflammatory and neural repair activity.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the ability to successfully develop and commercialize SP16 and the impact of the transaction on the stock price.
- Risks and Contingencies:
- Actual results may differ materially due to risks regarding continued Nasdaq listing, development success, and commercialization.
- Issued securities are unregistered and cannot be sold in the U.S. absent registration or an exemption.
- Conversion of Preferred Stock is subject to beneficial ownership limitations and stockholder approval.
- Next Steps: The Company expects to file a proxy statement for stockholder approval of the issuance proposals and the adjournment of the meeting if necessary.
Investor Verification Checklist
- Valuation of Consideration: Verify the fair market value of the 191,017 Common Shares and 89.5939 Series A-2 Preferred Shares issued to each counterparty to assess the total cost of the license.
- Conversion Mechanics: Review the Certificate of Designation (Exhibit 3.1) to understand the specific "Beneficial Ownership Limitation" thresholds that may delay or prevent the conversion of Series A-2 Preferred Stock into Common Stock.
- Dilution Impact: Calculate the potential dilution from the conversion of Series A-2 Preferred Stock (10,000:1 ratio) and the existing Series A and A-1 Preferred Stock.
- Stockholder Approval: Monitor the upcoming proxy statement for the specific voting requirements and dates for the "Meeting Proposals" regarding the issuance of shares.
- Exhibit Review: Examine the full text of the Exclusive License Agreement (Exhibit 10.1) for any undisclosed milestones, development obligations, or termination rights not summarized in the 8-K.